Carla Borri Voltattorni, Itamar Kass, Nathan Cowieson, Malcolm Buckle, David Perahia, Mauricio G. S. Costa, Daniel Christ, David B. Langley, David E. Hoke, Eugenia Pennacchietti, Ian R. Mackay, Oded Kleifeld, Cyril F. Reboul, Hervé Leh, Benjamin T. Porebski, Ashley M. Buckle, Julia M. McCoey, Brendan Roome, Daniela De Biase, Alessandro Paiardini, Monash University [Clayton], Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP), Australian Synchrotron [Clayton], Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Department of Medical-Surgical Sciences and Biotechnologies, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome]-Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, University of Verona (UNIVR), Garvan Institute of Medical Research [Darlinghurst, Australia], Department of Biochemical Sciences 'Rossi Fanelli', Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], and M.G.S.C. was financially supported by a French–Brazilian Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Comité Français d'Evaluation de la Coopération Scientifique et Universitaire avec le Brésil Collaboration Project. E.P. was the recipient of a bursary from the Istituto Pasteur-Fondazione Cenci Bolognetti. D.C. and A.M.B. hold research fellowships from the National Health and Medical Research Council. D.D.B. thanks Fondazione Roma for partially supporting this work. This research was supported by the Victorian Life Sciences Computation Initiative Life Sciences Computation Centre, a collaboration between Melbourne, Monash, and La Trobe Universities and an initiative of the Victorian Government, Australia.
International audience; The human neuroendocrine enzyme glutamate decarboxylase (GAD) catalyses the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) using pyridoxal 5′-phosphate as a cofactor. GAD exists as two isoforms named according to their respective molecular weights: GAD65 and GAD67. Although cytosolic GAD67 is typically saturated with the cofactor (holoGAD67) and constitutively active to produce basal levels of GABA, the membrane-associated GAD65 exists mainly as the inactive apo form. GAD65, but not GAD67, is a prevalent autoantigen, with autoantibodies to GAD65 being detected at high frequency in patients with autoimmune (type 1) diabetes and certain other autoimmune disorders. The significance of GAD65 autoinactivation into the apo form for regulation of neu-rotransmitter levels and autoantibody reactivity is not understood. We have used computational and experimental approaches to decipher the nature of the holo → apo conversion in GAD65 and thus, its mechanism of autoinactivation. Molecular dynamics simulations of GAD65 reveal coupling between the C-terminal domain, catalytic loop, and pyridoxal 5′-phosphate–binding domain that drives structural rearrangement, dimer opening, and autoinactivation, consistent with limited proteolysis fragmentation patterns. Together with small-angle X-ray scattering and fluorescence spectroscopy data, our findings are consistent with apoGAD65 existing as an ensemble of conformations. Antibody-binding kinetics suggest a mechanism of mutually induced conformational changes, implicating the flexibility of apoGAD65 in its autoantigenicity. Although conformational diversity may provide a mechanism for cofactor-controlled regulation of neurotransmitter biosyn-thesis, it may also come at a cost of insufficient development of immune self-tolerance that favors the production of GAD65 autoantibodies.